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QUEST FOR VACCINES TO TREAT ADDICTION 
Rachel Florence 
ABSTRACT 
Drug addiction is a prime example of biochemical psychology. When people use drugs 
such as nicotine, they trigger dopamine receptors in the brain, causing a pleasurable sensation. 
People want to repeat the feeling and thus get addicted to the drug. With the development of a 
vaccine to treat addiction, researchers attempt to prevent drugs from crossing over the blood-
brain barrier and triggering the dopamine receptors. Experiments and clinical trials prove the 
efficacy of the nicotine vaccine. However, Phase III trials and additional research are 
necessary before the vaccine can be launched for public use.   
INTRODUCTION 
Addiction is one of the greatest issues facing our society today. Thousands of 
people struggle with smoking, drugs, and other addictions on a daily basis. What starts 
as one cigarette or one sip of alcohol often develops into a daily necessity or an ever-
present need. However, it is not the cigarette or alcohol that satiates a person; it is the 
chemical reaction of the dopamine receptors that the addictive substance triggers in 
the brain that satisfies (Koob and Moal 2001). Addiction is a classic case of 
biochemical psychology, in which certain activities in the brain cause specific forms of 
behavior. In this case, the chemical reaction occurring in the brain in response to a 
drug causes the user to feel a certain reward. This eventually causes one to become 
dependent on the drug, to the extent that one is willing to forego all ethical limits to 
obtain more of it. Numerous researchers have attempted to find a way to help addicts 
recover (Koob and Moal 2001). Previous experiments as well as cutting-edge research 
have furthered this discovery. Researchers have developed a vaccine to aid in the 
treatment of nicotine addiction and restore normal brain receptor activities. However, 
what is the efficacy of the "nicotine vaccine" in treating smokers addicted to nicotine? 
Before analyzing the effectiveness of the vaccine, a complete understanding of 
dopamine receptors and their effects on the body and behavior must be gained.  
THE BRAIN-BEHAVIOR CONNECTION: DOPAMINE RECEPTORS 
Psychologists and scientists have been mystified by the brain-behavior 
connection in drug or alcohol abuse and have been trying to determine how to treat 
addiction.  Drugs and other addictive substances cause a surge in levels of a brain 
chemical called dopamine, the neurotransmitter that is responsible for feelings of 
pleasure. The brain remembers this pleasure and wants to repeat it (Long 2011). 
Neurons containing the dopamine receptors are clustered in the substantia nigra, an 
area in the midbrain (Schultz 2010). The pleasure sensation creates the motivation for 
a person to proactively pursue activities such as eating and drinking that are crucial for 
survival.  A person is driven to perform these vital functions because the brain is 
conditioned to expect the dopamine rush that accompanies them. Drugs such as 
methamphetamine, heroin, and cocaine produce their effects by acting on the flow of 
neurotransmitters and affecting the brain chemistry (Schultz 2010). They can cause 
profound changes in human behavior (Wise and Rompre 1998) that can have negative 
consequences in varying areas of an individual's life (Chandler et al. 2009).  
Widely documented experimental evidence suggests that the mesolimbic 
dopamine system is hypofunctional in the addicted brain (Melis et al. 2005). When 
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using addictive drugs, the brain is flooded with up to ten times the normal amount of 
dopamine. The mesolimbic dopamine system becomes hypofunctional due to down-
regulation of the dopamine receptor because of excess dopamine present when certain 
addictive drugs are used. By decreasing the dopamine (DA) system function in 
addicted subjects, there will be a decreased interest in non-drug related stimuli and 
increased sensitivity to the drug of choice (Melis et al. 2005). When a user’s brain 
adapts to a higher level of dopamine to get pleasure, it begins associating the addictive 
drug with this neurochemical reward, and eventually, the drugs create a scenario that 
only they can meet (Diana 2011). This process leads to addiction, in which a person is 
left with a drive to compulsively take the drug, conditioned to expect artificially high 
levels of the neurotransmitter. The brain begins to require more dopamine than it can 
naturally produce, and it becomes dependent on the addictive drug, which never 
actually satisfies the need it created (Kosten 2011). 
Normally, dopamine conditions us to do what we need to do to continue 
surviving. Regulation of dopamine plays a crucial role in our mental and physical 
health. However, just as food is linked to survival in day-to-day living, addictive drugs 
triggering the release of dopamine begin to take on the same significance for the 
addict. The need to obtain and take drugs becomes more important than any other 
need, including truly vital behaviors like eating. Eventually, all ethical guidelines in a 
person's life, such as family, work, and community obligations and values, are lost to 
the disease of addiction (Koob and Moal 2001).  When the brain's dopamine receptor 
is down-regulated, greater amounts of dopamine are required to induce the normal 
effect. Eventually, the disrupted dopamine system renders the addict incapable of 
feeling any pleasure even from the drugs they seek to feed their addiction. The lack of 
control causes people who are addicted to continue using drugs, even when the drugs 
have lost their power to reward (Diana 2011).   
Based on the above, one form of treatment used to treat addicted patients is to 
block entry of the addictive drug into the brain receptor system (Kenny et al. 2006). In 
this way, the DA system hypofunction will eventually revert to normal functioning 
with time.  
NICOTINE ADDICTION AND TREATMENT 
Cigarette smoking is the most common cause of death in industrialized 
countries. Thirty percent of all deaths in smokers from 35-69 years of age are due to 
chronic smoking. Though there are many forms of medication available for the 
addiction, there is still an extremely low success rate for people who have tried to quit 
smoking. According to the American Lung Association, nearly half of U.S. smokers try 
to quit each year, and only 4% to 7% of the people who make the attempt are 
successful. Norman Edelman, the Chief Medical Officer of the American Lung 
Association, says that at best, only one out of three people trying to quit are successful 
(American Lung Association 2011).  
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Therefore, a new approach to treating addiction has been developed. This 
technique utilizes injected vaccines to block addictive substances from reaching the 
brain. As indicated in Figure 1, the vaccine induces the immune system to produce 
antibodies that bind to nicotine. This prevents the nicotine from crossing the blood-
brain barrier and acting on dopamine receptors in the brain. When people smoke, the 
nicotine inhaled from tobacco moves 
from the lungs to the bloodstream, and 
up to the smoker's brain within 
seconds. There, nicotine triggers a 
number of chemical responses, one of 
which involves the dopamine receptors, 
creating feelings of pleasure and a 
variety of neural effects that initiate and 
maintain tobacco dependence. The 
sensation lasts minutes. However, as 
the nicotine levels drop, smokers feel 
agitated, a symptom of nicotine 
withdrawal. In order to relieve 
discomfort, they often light another 
cigarette, beginning a vicious cycle of 
addictive smoking. Therefore, efforts to 
develop treatment for people addicted 
to smoking have focused on targeting 
neural pathways involved in nicotine 
addiction (Hall 2005).  
When people take addictive 
drugs, the drug molecules travel 
through the bloodstream to the brain. 
Because addictive drugs are so small, 
they bypass the immune system 
completely. However, using the 
vaccine, scientists attach molecules 
similar to addictive drugs to much 
bigger antigens, such as deactivated 
versions of the common cold virus 
(Long 2011).  
When injected into lab animals and people, these so-called conjugate vaccines 
spur the immune system to create antibodies to fight the tiny, addictive drug molecules 
(Kosten 2011). The antibodies attach to molecules of nicotine and cocaine before they 
cross the blood-brain barrier, thereby blocking them from triggering the pleasure 
centers in the brain (Hall 2005).  
Vaccination against nicotine can reduce the risk of relapse in addicted smokers 
by easing the pharmacological effects of nicotine for the first few months after quitting, 
the period when most smokers relapse (Hall 2005). Unlike prior medications that 
worked via the brain, addictive-treatment vaccines work in the bloodstream (Long 
2011).  
Figure 1: With the administration of the vaccine, 
the body produces antibodies that bind to nicotine 
molecules and prevent them from crossing the 
blood brain barrier. Source: Long 2011 
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Vaccines against nicotine are a promising concept in smoking cessation 
research. This is because it can aid current smokers attempting to quit, former smokers 
wanting to avoid relapse, and adolescent smokers from becoming confirmed smokers. 
Because nicotine is the pharmacological agent controlling the rate of cigarette smoking, 
by reducing the rate and extent of uptake in the brain, researchers can attempt to treat 
the addiction (Vocci and Chiang 2001). Even if the smoker increases the dosage of 
nicotine, the rewarding effect would still be circumvented by the vaccine, hopefully 
ensuring that the lapse would not lead to daily smoking (Khoury et al. 2003). 
However, the vaccine does not combat cravings. They simply trick the body to reject 
drugs as if they are foreign pathogens. The vaccine also has the potential to work on 
many drugs aside from nicotine, such as cocaine and heroin, amongst other addictive 
substances.  
VACCINE FORMATION AND ADMINISTRATION 
Since nicotine is extremely small (molecular weight =167 kD) and therefore not 
immunogenic, the body does not create antibodies against it. By using a linker such as 
succinic acid, researchers can convert nicotine to an immunogenic carrier protein to 
form an immunogen, a conjugate nicotine vaccine. Multiple types of carrier proteins 
have been used, such as keyhole limpet hemocyanine, recombinant cholera toxin B 
subunit, and recombinant psuedomonas exoprotein A. The latter two have been used 
in vaccines administered to humans before. The vaccines are then mixed with an 
adjuvant such as alum, to enhance the immune response (Hieda et al. 1997).  
The ideal vaccine elicits antibodies that have the characteristics of 
immunogenicity, specificity, and affinity to bind to nicotine. Immunogenicity refers to 
the maximally effective serum concentration of antibody throughout the period of 
interest. In that way, there will be a higher ratio of antibody to nicotine to increase 
binding of nicotine to serum. Affinity refers to the strength of the antibodies binding to 
the nicotine, and specificity refers to the extent that antibodies bind to nicotine as 
opposed to other compounds (Hall 2005).  
EXPERIMENTATION PERFORMED WITH ANIMALS 
Studies performed with animals have proven that attaching nicotine to a viable 
antigenic protein produces antibodies that have a high affinity for nicotine (Hall 2005). 
A series of 2-4 injections of vaccine was given to rats over 4-8 weeks. The vaccine was 
aimed at eliciting higher serum concentration of nicotine specific antibodies that would 
not bind to nicotine metabolites (Pentel and Malin 2002). When the rats were 
vaccinated, they were given a single dose of nicotine, equivalent to the nicotine 
absorbed by a smoker from two cigarettes. The researchers then tested the serum and 
found that the nicotine delivered to the brain 1-3 minutes later was 60% less than that 
of the control group.  Even when the rats received heavier doses, equivalent to that of 
a chronic smoker, vaccination remained effective in reducing the early distribution of 
each dose to the brain. Vaccination of rats reduced the nicotine-induced release of 
dopamine from the nucleus accumbens, a neurochemical event that is thought to be a 
key mediator of nicotine dependence (Pentel and Malin 2002). 
These results indicate that there is potential usage for vaccines in the 
prevention of relapse. With the effect of the vaccine and the antibodies attacking the 
nicotine, the nicotine fails to pass through the blood-brain barrier and affect the 
dopamine receptors. By staying in the blood, there is no pleasurable response to the 
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nicotine. Cigarette smokers who quit often experience cravings and thus resume 
smoking to relieve their discomfort. However, if the vaccine renders the cigarette 
ineffective, the smokers will be less likely to smoke a cigarette. A downside of the 
experiment was that it only managed to prevent 60% of the nicotine from reaching the 
receptors. 
Investigators at the University of Minnesota also performed experiments with a 
vaccine to treat addiction to nicotine (Keyler et al. 2008). They began by taking a 
group of rats and injecting them with different types of proteins—proteins that would 
bind to the nicotine and attract the antibodies, preventing them from passing through 
to the brain. The experiment had three experimental groups, each injected with a 
different type of binding protein. The control group was a group of rats who received 
no protein injections at all. After three series of vaccinations, the rats were 
anesthetized with dropiridol/fentanyl, and then injected with .03/ mg/kg of 6-
CMUNic, 3-AmNic, and Bivalent over 10 sec via the jugular cannula. The rats were 
decapitated 3 minutes later and levels in the blood and brain were collected and stored 
at -20 degrees Celsius until processed. Serum and brain protein concentrations, 
nicotine protein binding parameters, and serum NicAb concentrations were compared 
among groups by one way ANOVA and individual comparisons were analyzed by t-
test. As seen in Figure 2, the results indicated that each of the vaccines increased the 
total serum nicotine concentration, and reduced the nicotine concentration in the brain 
compared to the control group.   
The results indicate that it is 
possible to design more than one 
immunological distinct hapten from a small 
molecule such as nicotine to inject via 
vaccine to bind to nicotine and prevent it 
from crossing the blood-brain barrier. The 
fact that the Bivalent showed evidence for 
antibodies in the blood, and lack thereof in 
the brain, shows the success of having the 
antibodies bind to the nicotine vaccine. The 
results show potential for using the vaccine 
to treat addiction for nicotine and ensure 
that the dopamine receptors are not 
affected by the drug (Keyler et al. 2008).  
CLINICAL TRIALS   
Researchers at Maastricht 
University extended the studies to human 
subjects. In this case, the researchers 
evaluated the safety and immunogenicity of 
four doses of a nicotine vaccine in smokers 
and non-smokers. The subjects were in 
good physical and mental health. Each 
volunteer either received an injection of a 
placebo in the control group, or the vaccine 
in the experimental group. In this case, the 
Figure 2: Results indicating the decreased 
nicotine levels in the blood of rats that were 
vaccinated, as well as the increased nicotine 
levels in the brains of non-vaccinated rats. 
Source: Keyler et al. 2008  
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scientists were not trying to see how much nicotine reached the brain. They were 
attempting to measure the success of the vaccine in creating nicotine-specific 
antibodies. The results would lead scientists one step further in treating subjects 
addicted to nicotine. The subjects received a vaccination of 3'-aminomethylnicotine 
conjugated to detoxified Pseudomonas aeruginosa r-exoprotein A each week. At first, 
no difference was seen between the two groups. However, after 21 days, 7 days after 
the second vaccination, significant increase in the geometric mean titer (GMT) levels 
of nicotine-specific antibodies were observed in the smokers. Nicotine-specific 
antibody levels rose to a GMT of at least 8 at day 49, and at least 10.8 at day 217. With 
each additional vaccination, the level continuously rose. These results indicate that the 
immunogenicity of the vaccine was not impeded by the presence of nicotine, thus 
providing evidence in humans that the vaccine used may represent a feasible strategy 
for evoking type-specific antibodies against nicotine. With these type-specific 
antibodies, the body can ward off nicotine and prevent it from reaching the brain 
(Wagena et al. 2008).  
Researchers at Yale University performed a similar experiment testing the 
therapeutic effects of a cocaine vaccine, using the same technique as the nicotine 
vaccine. The researchers used 34 former cocaine abusers as their experimental group. 
They were divided up and each was given a different dosage of the vaccine, 8 at 13 
micrograms of the active vaccine, 10 at 82 micrograms, and 10 at 709 micrograms. 
Two subjects in each group represented the control group who received a placebo. 
Each group got an intramuscular injection for up to 2 months and was monitored for 
safety and antibody production for 3 months. Twenty-seven of the subjects completed 
the full course of three injections. However, only 24 returned for the final scheduled 
visit on day 84. The vaccine had no drug-related adverse effects, but three subjects at 
the highest dose experienced brief twitching after being injected (Martell et al. 2007). 
Antibody levels were correlated with vaccine dosage and number of injections. 
Anti-cocaine antibodies were first detected after the second injection. The number of 
antibodies peaked after 3 months of treatment and then declined to baseline by 1 year. 
The therapeutic vaccine was well tolerated, with dose related increases in antibody 
levels, and a high proportion of patients recruited into the study were retained (Martell 
et al. 2007). 
Another experiment was performed using a vaccine to treat cocaine 
dependence. Eighteen subjects were tested with dose-escalation over fourteen weeks. 
Ten subjects received four 100 mg injections over the course of eight weeks. The other 
eight subjects received five 400 mg injections over twelve weeks. The urine 
toxicologies and cocaine antibody titers were compared, three times each week.  
Sixteen of the 18 subjects completed the study. The 2000 mg total dose group 
had significantly higher mean antibody titer response (2000 units) than the 400 mg 
total dose group. Despite the fact that there were relapses in both groups, the subjects 
said they lost the euphoric effect of cocaine at the six month follow-ups, 63% in the 400 
mg and 100% in the 2000 mg groups.  
The conjugated vaccine to treat cocaine addiction was well-tolerated and the 
antibodies were prevalent for at least six months. Additionally, the subjects who 
received the more intense vaccination schedule had less likelihood of using cocaine. 
These experiments prove that vaccines were effective in raising the antibody 
level in the body, as well as preventing the drugs from reaching the dopamine 
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receptors. However, the experimental groups were small and the researchers did not 
extend the experiment to see how long the effects lasted and if the dopamine receptor 
levels were up-graded and normal levels restored.  
Multiple pharmaceutical companies are performing vaccine clinical trials as 
well. The adjuncts used in the clinical trials are known as alum hydroxide or 
phosphate. All of the clinical trials have administered the vaccine via injection. The 
company Cytos has successfully completed a Phase I clinical trial involving 40 non-
smoking subjects who showed no unexpected toxicities. In Phase II of the study, 
individuals with antibodies in the highest percentile were able to avoid relapse to 
cigarette consumption for longer than the subjects who received a placebo vaccine. 
Abstinence rates in subjects with lower antibody responses were not significantly 
different from those in the placebo group (Escobar-Chavez et al. 2011). This 
experiment proved that elevated antibody levels are effective in preventing relapse to 
cigarette consumption. 
Cytos's nicotine vaccine program now collaborated with Novartis AG. 
Together they performed a double-blind placebo-controlled Phase I study evaluating 
immunogenicity and tolerability of the vaccine. The study contained four groups of 10 
non-smoking subjects who were given different doses of the vaccine. All of the subjects 
evaluated responded with high levels of nicotine-specific antibodies and a long-lasting 
immune response. Up to half of the patients reported negative effects such as muscle 
aches, fever, and chills.  Those symptoms disappeared within one day, and the elevated 
antibody level declined over time. 
In Phase II of the clinical trial, a group of 341 smokers were divided: two thirds 
received the active vaccine and one third received a placebo. Afterwards, five 
injections of 100 mg of vaccine conjugate were given monthly and the subjects received 
counseling for the first three months. The subjects were required to abstain from 
smoking from week 8 to week 52 after receiving treatment. The researchers used self-
reporting and biochemical markers to evaluate that the subjects were adhering to the 
regulations.  The participants reacted as predicted. The two thirds receiving the active 
vaccine developed elevated levels of antibodies, while the control group did not. 
Though the vaccine was tolerated, there were some side effects such as flu-like 
symptoms. However, the effects only lasted for one day.  
In May 2005, six-month results were published, and later that year, 12-month 
results were published. According to the results of the antibody levels, the smokers 
were divided into three groups: low, medium, and high responders. The high 
responders group had continuous abstinence after 6 to 12 months of 57% (P=0.004 as 
compared to the placebo group) and 42% respectively. The medium responders group 
had a result of 32% and 21% respectively, and the low responders group had 32% and 
26% respectively. The relatively high continuous abstinence rate for the placebo group 
was 32% and 26%.  
Another study Cytos performed with healthy volunteers evaluated giving 300 
mg per injection as opposed to 11 mg. The higher dose induced a greater mean 
antibody production that was four times higher than the initial Phase II study. The 
company also reported new formulations reducing the incidents of fever and flu-like 
symptoms to about 10% as opposed to the original 60% (Escobar-Chavez et al. 2011). 
The clinical trials performed by Cytos indicated the success of the vaccine in 
treating nicotine addiction. The subjects with increased levels of antibody production 
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maintained their smoking prevention and abstained from relapsing for longer periods 
of time. Immunization against nicotine can significantly ease some behavioral effects of 
nicotine. The results of these experiments suggest that immunologic intervention could 
have use in the treatment of tobacco dependence. However, further research and 
clinical trials are necessary to validate that vaccinations facilitate abstinence from 
nicotine use (Escobar-Chavez et al. 2011). 
POTENTIAL FOR THE NICOTINE VACCINE 
The nicotine vaccine certainly shows some degree of efficacy. Overall, the data 
indicated in the experiments and clinical trials support the vaccine in preventing 
nicotine from affecting the dopamine receptors. Clinically, though, the vaccine will not 
replace existing medication. Nicotine replacement therapy, such as bupropion and 
nortriptyline, will still be the main form of treatment. However, the vaccine can lessen 
the rewarding effects of nicotine, something which existing therapies cannot do 
significantly, thereby complementing current treatment (Escobar-Chavez et al. 2011).  
The nicotine vaccine can also be useful in relapse prevention by blocking the 
effects of using a cigarette. Vaccination can also be done while the individual is still 
smoking, thereby preparing the individual to quit. The vaccine may also have a 
possible role in preventing high-risk teens from becoming completely addicted to 
smoking. However, that will require additional confidence and safety assurances aside 
from proof of efficacy. 
Most importantly, vaccination can play a role in aiding individuals who are 
taking proactive steps to a complete recovery. Although research suggests that 
immunologic intervention can play an important role in treatment of tobacco addicts, 
the patients first need to be motivated to quit. The vaccine does not treat the non-
pharmacological factors that maintain tobacco dependence. By giving the vaccine in 
conjunction with behavioral intervention, patients can maximize the results and may 
quit their nicotine-dependence.  
More reports on the vaccine will be publicized within the coming year. Phase 
III trials and marketing launch dates for nicotine vaccines have yet to be announced. 
However, the results of the experiments and clinical trials performed thus far are 
indicative of the possibility of successfully distributing a vaccine to induce type-specific 
antibodies to prevent nicotine from entering the brain (Long 2011). These experiments 
provide a basis for creating vaccines to treat other substances as well, using the same 
strategy. Scientists are merely steps away from succeeding in creating an effective 
vaccine against nicotine, and perhaps with that success, they will attempt to create 
further vaccines type-specific for antibodies to bond to other addictive substances. 
DISADVANTAGES/ETHICAL ISSUES 
There are numerous ethical issues that arise with the possibility of producing 
and distributing a nicotine vaccine. Firstly, misconceptions may arise that the vaccine 
will give lifelong immunity against nicotine and may cause parents to vaccinate their 
children, and as minors, children will be unable to dissent. Some may say that parents 
have a right to protect their children, while others may fight this view, namely, tobacco 
producers. Additionally, there is a danger that people may overdose on drugs after 
receiving the vaccine due to their inability to feel pleasure from the drugs. 
On the other hand, the vaccine used for treatment of addiction has many 
advantages. Most importantly, though not eliminating the cravings, the vaccine will 
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help the addict stick to his recovery, in that after his injection he will be free of the 
drug induced chemical reactions that he relied on so heavily (Kosten 2011). With this-
once-a-month vaccine, the recovering addict has a stronger chance of maintaining his 
treatment plan, as it only takes a monthly injection to ensure that he does not feel the 
affects of succumbing to his desire to relapse, and thus can overcome the initial most 
difficult moths of addiction treatment (Long 2011). The most crucial part of any drug 
treatment is the prevention of relapse. With the antibodies from the vaccine remaining 
within the user's system for an entire month, the user will be protected from relapses 
throughout that time period, and hopefully remain drug-free by choice after that.  
Additionally, the vaccine poses minimal danger to the subject's health and 
normal brain functioning. By blocking the brain from receiving the chemicals from the 
drugs, the user will be able to stop his behavior and control his addiction.  The vaccine 
can also be used alongside psychological therapy because it does not affect normal 
brain functioning; it prevents both the vaccine and the drug from entering the brain 
(Long 2011). Another advantage of the vaccine is that it saves time, since it only has to 
be given once a month. It saves money as well, as other forms of pills, compresses and 
treatments may be minimized or eliminated. Though it is advisable for subjects of 
addiction to see a psychologist continuously, the vaccine helps prevent a relapse 
because they will stop using the drug once they realize it has no effect on them, thus 
eliminating relapse costs.  
Another major advantage is that the addictive substance is not being treated 
with another addictive substance, drug for drug. With the vaccine, the effect of the 
addictive substance is being eliminated, while refraining from adding additional 
potentially addictive substances to the body. Traditional addiction treatments typically 
involve medications that mimic a drug in the brain. For example, methadone will stand 
in for heroine and a nicotine patch will substitute for cigarettes. Other medications 
block activity in the brain's reward system, such as Vivitrol injections for alcoholics 
and Pfizer Inc.'s Chantix pills that block the brain's pleasure receptors from being 
activated when people smoke. Some of these drugs function inside the brain and thus 
can pose potential damage to the brain. Warnings include depression and suicidal 
thoughts (Long 2011). On the other hand, vaccines pose no risk to normal brain 
functioning. 
CONCLUSION 
Addiction is a clear indicator of biological and biochemical psychology and the 
way the brain controls behavior. The brain plays a strong role in human behavior in 
that ultimately, addicts are craving the chemical reaction that the drug causes. Though 
there are many medications for addicts, psychologists have noted that the success rate 
of treatment for drug-abuse is unfortunately low (Koob and Moal 2001). The fact that 
the development of a vaccine may be able to treat addiction poses a new hope for 
addicts' recovery. 
The idea of using the body’s innate immune system functions to treat addictions 
is brilliant. By using antibodies, no risk is posed to the brain or normal functioning. 
This technique may also be implemented for other health issues that involve chemicals 
reaching the brain. The development of such a vaccine can be the basis for further 
development and treatment for other dangerous chemicals that reach the brain. Using 
vaccines to treat addiction is just one step in using the antibodies already in our bodies 
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to treat illnesses. Antibodies are G-d's army to fight disease; why not utilize them to 
their complete capacity? 
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